MedTrace Logo

Gene Therapy for Haemophilia A.

NCT03001830 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-03-05

No results posted yet for this study

Summary

The GO-8 study focuses on assessing safety and efficacy of gene therapy for patients with severe haemophilia A

Conditions

Interventions

BIOLOGICAL

AAV2/8-HLP-FVIII-V3

Infusion of AAV2/8-HLP-FVIII-V3

Sponsors & Collaborators

Principal Investigators

  • Pratima Chowdary, MD · Royal Free London NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-14
Primary Completion
2029-01-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03001830 on ClinicalTrials.gov